Advertisement

Document › Details
Xlife Sciences AG. (11/4/19). "Press Release: Xlife Siences AG. New Project in the Portfolio". Zurich.
![]() |
Organisation | Xlife Sciences AG |
Organisation 2 | Saniva Diagnostics GmbH | |
![]() |
Product | diagnostic device, clinical |
Product 2 | venture capital | |
![]() |
Index term | Saniva Diagnostics–Xlife Sciences: investment, 201911 investment by Xlife Sciences AG in Saniva Diagnostics GmbH |
We are pleased to announce that Xlife Sciences AG has added saniva diagnostics GmbH to the portfolio.
saniva diagnostics GmbH
Detecting diseases at an early stage is crucial to modern medical science. The timing of a diagnosis can significantly impact the chances of healing and the effectiveness of therapy. saniva diagnostics GmbH, a spin-off of the University Hospital Jena is developing a screening instrument to detect neurodegenerative diseases such as Parkinson or dementia at a very early stage. This screening instrument works by analyzing human movement. For more information, please visit: www.sanivadiagnostics.com
Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and futureoriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Record changed: 2019-11-16 |
Advertisement

More documents for Xlife Sciences AG
- [1] Indivumed GmbH. (3/18/21). "Press Release: Indivumed Announces Expansion into Drug Development, Formation of Ix Therapeutics. Joint Venture with Xlife Sciences". Hamburg....
- [2] Velabs Therapeutics GmbH. (1/7/20). "Press Release: Velabs Therapeutics Receives Exclusive Licence from Alytas Therapeutics for the Development of Therapeutic Antibodies as Senolytics". Heidelberg & Jena....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top